Summary

The global Aesthetic Injectables market size is predicted to grow from US$ 9568 million in 2025 to US$ 23830 million in 2032; it is expected to grow at a CAGR of 14.1% from 2026 to 2032.
Aesthetic Injectables refer to professionally administered injectable products used in medical aesthetics to modify facial muscle activity, restore soft-tissue volume, correct wrinkles and folds, improve facial contours, stimulate collagen remodeling, and enhance skin quality. The market is centered on standardized commercial products supplied to licensed medical and aesthetic practitioners and covers Aesthetic Botulinum Toxin, HA-based Injectables, PLLA & PDLLA Injectables, CaHA Injectables, and other qualified aesthetic injectable products. Product formats include lyophilized or ready-to-use neuromodulators, prefilled injectable gels, reconstituted biostimulatory preparations, and other regulated injectable formulations. Product performance is differentiated by treatment mechanism, rheological and material characteristics, injection depth, anatomical indication, onset of effect, duration, reversibility, safety profile, and practitioner handling characteristics. FDA guidance similarly distinguishes injectable botulinum toxin products from dermal fillers, while recognizing dermal fillers as injectable soft-tissue implants used to create smoother or fuller facial contours. The primary downstream settings are medical aesthetic clinics and licensed medspas, dermatology clinics, plastic and cosmetic surgery clinics, hospitals and medical centers, and other licensed medical settings.
Key Findings
Global Aesthetic Injectables sales volume reached approximately 30.5 million equivalent syringes and vials in 2025
Average manufacturer-level pricing was approximately US$320.7 per equivalent commercial unit in 2025
Aesthetic Botulinum Toxin remained the largest product category, while HA-based Injectables formed the second major revenue pool
Demand remains centered on professionally administered treatments where safety, practitioner expertise and regulatory compliance materially influence product adoption
Market Trends
The Aesthetic Injectables market is shifting from single-indication wrinkle correction toward more comprehensive and individualized treatment strategies that combine neuromodulation, volume restoration, structural support, collagen stimulation and skin-quality improvement. Botulinum toxin and hyaluronic acid fillers remain the two most widely performed non-surgical aesthetic procedures globally, demonstrating the continued commercial importance of established injectable categories. At the same time, product innovation is increasingly focused on more natural outcomes, differentiated duration, improved rheology, lower treatment burden and regenerative or biostimulatory effects. This is creating a broader role for PLLA & PDLLA and CaHA products alongside traditional HA fillers. The market is also becoming more portfolio-driven: physicians increasingly select different injectable technologies according to anatomical area, desired treatment effect and patient age rather than relying on a single filler platform. Recent company performance also indicates that category momentum is not uniform; neuromodulators and biostimulatory products have shown stronger momentum in some markets while conventional fillers have faced periods of softer demand, reinforcing the importance of differentiated product positioning and broader injectable portfolios.
Market Dynamics
Drivers
Growth in Aesthetic Injectables is supported by the large and expanding global base of non-surgical aesthetic procedures, increasing acceptance of minimally invasive treatments and continuing demand for facial rejuvenation with relatively limited recovery time. ISAPS reported approximately 20.5 million non-surgical procedures performed by plastic surgeons in 2024, with botulinum toxin and hyaluronic acid fillers ranking as the two most popular non-surgical procedures. Product innovation is also broadening the addressable patient population by giving practitioners greater flexibility in treatment duration, facial anatomy, tissue layer and aesthetic objective. Wider physician training, expansion of licensed medical-aesthetic networks and new regulatory approvals in major markets further support product availability. Importantly, the market benefits from repeat-treatment characteristics: neuromodulators, HA fillers and many biostimulatory products require periodic retreatment or staged treatment protocols, creating recurring product demand rather than relying solely on first-time patients.
Restraints
Market expansion is constrained by the discretionary nature of aesthetic expenditure, regulatory requirements, treatment cost and sensitivity of premium injectable demand to consumer confidence. Different jurisdictions apply different approval, registration and professional-use requirements, increasing the cost and time required for manufacturers to commercialize products globally. The filler market can also experience periods of slower demand even when the wider injectable category remains resilient; 2025 company disclosures showed softer performance for certain established HA filler portfolios while neuromodulators and selected biostimulatory products performed more strongly. In addition, product economics depend not only on the manufacturer selling price but also on physician training, clinic acquisition costs, distributor margins and treatment pricing. Competitive pricing from regional manufacturers, especially in HA fillers and botulinum toxin, can put pressure on established premium products and increase the importance of clinical evidence, brand reputation, injector preference and product differentiation.
Opportunities
Future market opportunities are increasingly associated with product differentiation rather than simple expansion of conventional filler volumes. Longer-lasting or faster-onset neuromodulators, differentiated HA rheology, collagen-stimulating injectables and combination treatment protocols can expand the range of aesthetic objectives addressed by injectable products. Biostimulatory approaches are particularly relevant where patients seek gradual tissue remodeling, structural improvement and more natural-looking results rather than immediate volumization alone; established injectable aesthetics companies are consequently expanding clinical evidence and indications around these technologies. Geographic expansion represents another opportunity. Manufacturers with regulatory approvals across the United States, Europe, China and other major markets can leverage established production platforms across a broader commercial base, while Asian manufacturers are increasingly extending toxin, filler and skin-quality portfolios internationally. Hugel, for example, reported continued overseas expansion of botulinum toxin and HA filler sales in 2025, illustrating the growing international role of Asian injectable manufacturers.
Challenges
The key long-term challenges are safety management, regulatory compliance, counterfeit products and increasingly crowded competitive positioning. Injectable aesthetics require professional administration because adverse outcomes can arise from incorrect injection technique, unsuitable anatomical placement or use of unapproved products. FDA guidance highlights serious dermal filler risks and advises against purchasing fillers from unauthorized online sources, while the agency has also issued warnings regarding unapproved and misbranded botulinum toxin products following reports of adverse events. These issues increase the importance of traceability, licensed distribution, physician education and post-market surveillance. At the commercial level, mature HA filler markets contain numerous products with similar headline indications, making differentiation increasingly dependent on material properties, clinical evidence, durability, handling characteristics and physician loyalty. Manufacturers must therefore balance regulatory investment and clinical development with competitive pricing while maintaining sufficient margins to support practitioner training and international market access.
Industry Chain Analysis
The upstream industry chain for Aesthetic Injectables varies significantly by technology. Aesthetic Botulinum Toxin depends on biological strain management, fermentation and purification capabilities, formulation excipients, sterile vial systems and stringent biologics quality control. HA-based Injectables require medical-grade hyaluronic acid, crosslinking and purification technologies, sterile formulation, prefilled syringes, needles and packaging systems. PLLA & PDLLA and CaHA products require controlled particle or microsphere characteristics, carrier systems and formulation technologies that influence injectability, tissue response and duration. Across all categories, upstream quality consistency is critical because small differences in purity, particle distribution, rheology, potency or sterility can materially affect product performance and regulatory acceptance.
Midstream value creation is concentrated in formulation development, aseptic manufacturing, fill-finish, clinical development, regulatory registration, brand development and professional medical education. Downstream products reach medical aesthetic clinics and licensed medspas, dermatology clinics, plastic and cosmetic surgery clinics, hospitals and other licensed medical settings through direct sales or authorized professional distribution. The industry generally supports attractive product-level margins because value is created through proprietary formulation, manufacturing know-how, clinical evidence, regulatory approval and practitioner confidence rather than through raw-material cost alone. However, profitability varies by category and company structure: vertically integrated manufacturers can retain a larger portion of product value, while licensing, outsourced production and multi-layer distribution models allocate economics across several participants.
Segment Insights
Aesthetic Botulinum Toxin remains the largest segment of the Aesthetic Injectables market and represents roughly half of global product revenue in the current research model. Its position is supported by a large repeat-treatment base, broad use for dynamic facial wrinkles and established physician familiarity. HA-based Injectables form the second-largest segment and account for roughly one-third of market revenue, supported by applications in facial volume restoration, contouring, wrinkle correction and lip enhancement. The FDA explicitly distinguishes botulinum toxin products from dermal fillers because the former act through neuromuscular modulation while fillers create structural volume or contour changes.
PLLA & PDLLA Injectables and CaHA Injectables remain smaller than the two established categories but occupy an increasingly important position in biostimulatory aesthetics. Their value proposition is based more heavily on collagen stimulation, tissue remodeling and structural improvement than on immediate gel-based filling alone. This creates differentiated use cases and can support premium positioning, although treatment protocols, onset and duration differ substantially from conventional HA fillers. Others remain a heterogeneous segment covering qualified injectable aesthetic materials outside the four primary categories. Overall, the market is therefore developing toward coexistence of neuromodulators, conventional fillers and biostimulatory products rather than replacement of one technology by another.
Downstream Market Opportunities
Medical aesthetic clinics and licensed medspas represent the core commercial channel for Aesthetic Injectables because they combine high procedure frequency, specialized injector capacity and recurring patient relationships. Dermatology clinics and plastic and cosmetic surgery clinics are also important because injectable treatments can complement broader facial rejuvenation and aesthetic treatment plans. Hospitals and medical centers are relevant where local regulation places injectable procedures within more formal medical environments. The strongest downstream opportunity is increasingly associated with protocol-based treatment rather than one-product transactions: practitioners can combine Aesthetic Botulinum Toxin, HA-based Injectables and biostimulatory products to address muscle activity, volume loss, contour, skin quality and structural aging in a coordinated plan. This increases the importance of physician education and portfolio breadth, while creating opportunities for suppliers capable of supporting multiple treatment objectives within the same professional channel.
Regional Insights
North America and Europe remain major high-value markets for Aesthetic Injectables, supported by established medical-aesthetic infrastructure, broad physician familiarity and commercial access to multiple toxin, filler and biostimulatory platforms. These regions also remain important launch markets for differentiated injectable technologies. Asia Pacific has a different competitive profile: it combines substantial procedure demand with a dense manufacturing base in South Korea and China, where producers have developed botulinum toxin, HA fillers, skin-quality injectables and regenerative-material platforms. International expansion by Asian manufacturers is increasing competitive pressure in markets historically dominated by Western brands; Hugel reported that overseas sales represented a growing share of its toxin and filler business in 2025, with particularly strong expansion in the Americas.
Regional opportunity is nevertheless highly dependent on regulation and physician-channel structure. Approval pathways, permitted indications, injector qualifications and distribution rules vary significantly across countries, so commercial success requires more than manufacturing scale alone. Mature markets favor clinical evidence, premium branding and physician loyalty, while developing medical-aesthetic markets provide opportunities for broader patient penetration and new product launches. Companies with products approved across several major regulatory jurisdictions are therefore positioned to spread development and manufacturing investment over a wider commercial base.
Competitive Landscape Analysis
The Aesthetic Injectables market has a layered competitive structure consisting of diversified global aesthetics companies, specialized botulinum toxin manufacturers, HA filler and biostimulatory specialists, and increasingly international Asian manufacturers. Established portfolio companies such as AbbVie, Galderma and Merz compete through broad product recognition, physician relationships, clinical development and multi-category portfolios, while Ipsen, Hugel, Medytox, Daewoong and Lanzhou Institute of Biological Products contribute important manufacturing positions in botulinum toxin. Teoxane, Croma-Pharma, Prollenium, CGBIO, PharmaResearch and other specialized manufacturers compete through filler rheology, material technologies and biostimulatory differentiation, while Bloomage Biotechnology, IMEIK and Shanghai Haohai represent an increasingly significant Chinese manufacturing base. Competitive advantage is becoming less dependent on a single established brand and more dependent on portfolio breadth, clinical differentiation, international approvals, reliable sterile manufacturing, physician training and channel execution. Recent company results also demonstrate that competitive momentum can shift between categories: Galderma reported double-digit growth in Injectable Aesthetics in 2025, while certain mature filler portfolios elsewhere experienced softer demand, indicating active share redistribution rather than uniform market growth.
Report Scope
LP Information, Inc. (LPI) ' newest research report, the “Aesthetic Injectables Industry Forecast” looks at past sales and reviews total world Aesthetic Injectables sales in 2025, providing a comprehensive analysis by region and market sector of projected Aesthetic Injectables sales for 2026 through 2032. With Aesthetic Injectables sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Aesthetic Injectables industry.
This Insight Report provides a comprehensive analysis of the global Aesthetic Injectables landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Aesthetic Injectables portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Aesthetic Injectables market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Aesthetic Injectables and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Aesthetic Injectables.
This report presents a comprehensive overview, market shares, and growth opportunities of Aesthetic Injectables market by product type, application, key manufacturers and key regions and countries.
Market Segmentation
Segmentation by Type:
Aesthetic Botulinum Toxin
HA-based Injectables
PLLA & PDLLA Injectables
CaHA Injectables
Others
Segmentation by Product Presentation:
Lyophilized Powder Vial
Ready-to-use Liquid Toxin
Reconstituted Microsphere/Polymer Vial
Others
Segmentation by Effect Duration:
Up to 6 Months
More than 6 Months to 12 Months
More than 12 Months to 24 Months
More than 24 Months / Semi-permanent
Segmentation by Application:
Medical Aesthetic Clinics & Licensed Medspas
Dermatology Clinics
Plastic & Cosmetic Surgery Clinics
Hospitals & Medical Centers
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
AbbVie Inc.
Galderma Group AG
Merz Pharma GmbH & Co. KGaA
Ipsen S.A.
Revance
Daewoong Pharmaceutical Co., Ltd.
Hugel, Inc.
Medytox Inc.
Huons BioPharma Co., Ltd.
LG Chem, Ltd.
Teoxane SA
Croma-Pharma GmbH
IBSA Institut Biochimique SA
Prollenium Medical Technologies Inc.
Laboratoires VIVACY
BioScience GmbH
MATEX LAB S.p.A.
SYMATESE
Tiger Aesthetics Medical, LLC
Mastelli S.r.l.
PharmaResearch Co., Ltd.
REGEN Biotech, Inc.
CGBIO Co., Ltd.
DEXLEVO Inc.
BioPlus Co., Ltd.
Humedix Co., Ltd.
Across Co., Ltd.
JETEMA Co., Ltd.
GENOSS Co., Ltd.
BNC Korea Co., Ltd.
SciVision Biotech Inc.
Sunmax Biotechnology Co., Ltd.
NPO Microgen
Huadong Medicine Co., Ltd.
Bloomage Biotechnology Corporation Limited
IMEIK Technology Development Co., Ltd.
Shanghai Haohai Biological Technology Co., Ltd.
Shanxi Jinbo Bio-Pharmaceutical Co., Ltd.
Lanzhou Institute of Biological Products Co., Ltd.
Bohus BioTech
Key Questions Addressed in this Report
What is the 10-year outlook for the global Aesthetic Injectables market?
What factors are driving Aesthetic Injectables market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Aesthetic Injectables market opportunities vary by end market size?
How does Aesthetic Injectables break out by Type, by Application?

ページTOPに戻る

Table of Contents

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats

2 Executive Summary
2.1 World Market Overview
2.1.1 Global Aesthetic Injectables Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Aesthetic Injectables by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Aesthetic Injectables by Country/Region, 2021, 2025 & 2032
2.2 Aesthetic Injectables Segment by Type
2.2.1 Aesthetic Botulinum Toxin
2.2.2 HA-based Injectables
2.2.3 PLLA & PDLLA Injectables
2.2.4 CaHA Injectables
2.2.5 Others
2.2.6 Aesthetic Injectables Sales by Type
2.2.6.1 Global Aesthetic Injectables Sales Market Share by Type (2021-2026)
2.2.6.2 Global Aesthetic Injectables Revenue and Market Share by Type (2021-2026)
2.2.6.3 Global Aesthetic Injectables Sale Price by Type (2021-2026)
2.3 Aesthetic Injectables Segment by Product Presentation
2.3.1 Lyophilized Powder Vial
2.3.2 Ready-to-use Liquid Toxin
2.3.3 Reconstituted Microsphere/Polymer Vial
2.3.4 Others
2.3.5 Aesthetic Injectables Sales by Product Presentation
2.3.5.1 Global Aesthetic Injectables Sales Market Share by Product Presentation (2021-2026)
2.3.5.2 Global Aesthetic Injectables Revenue and Market Share by Product Presentation (2021-2026)
2.3.5.3 Global Aesthetic Injectables Sale Price by Product Presentation (2021-2026)
2.4 Aesthetic Injectables Segment by Effect Duration
2.4.1 Up to 6 Months
2.4.2 More than 6 Months to 12 Months
2.4.3 More than 12 Months to 24 Months
2.4.4 More than 24 Months / Semi-permanent
2.4.5 Aesthetic Injectables Sales by Effect Duration
2.4.5.1 Global Aesthetic Injectables Sales Market Share by Effect Duration (2021-2026)
2.4.5.2 Global Aesthetic Injectables Revenue and Market Share by Effect Duration (2021-2026)
2.4.5.3 Global Aesthetic Injectables Sale Price by Effect Duration (2021-2026)
2.5 Aesthetic Injectables Segment by Application
2.5.1 Medical Aesthetic Clinics & Licensed Medspas
2.5.2 Dermatology Clinics
2.5.3 Plastic & Cosmetic Surgery Clinics
2.5.4 Hospitals & Medical Centers
2.5.5 Others
2.5.6 Aesthetic Injectables Sales by Application
2.5.6.1 Global Aesthetic Injectables Sale Market Share by Application (2021-2026)
2.5.6.2 Global Aesthetic Injectables Revenue and Market Share by Application (2021-2026)
2.5.6.3 Global Aesthetic Injectables Sale Price by Application (2021-2026)

3 Global by Company
3.1 Global Aesthetic Injectables Breakdown Data by Company
3.1.1 Global Aesthetic Injectables Annual Sales by Company (2021-2026)
3.1.2 Global Aesthetic Injectables Sales Market Share by Company (2021-2026)
3.2 Global Aesthetic Injectables Annual Revenue by Company (2021-2026)
3.2.1 Global Aesthetic Injectables Revenue by Company (2021-2026)
3.2.2 Global Aesthetic Injectables Revenue Market Share by Company (2021-2026)
3.3 Global Aesthetic Injectables Sale Price by Company
3.4 Key Manufacturers Aesthetic Injectables Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Aesthetic Injectables Product Location Distribution
3.4.2 Players Aesthetic Injectables Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy

4 World Historic Review for Aesthetic Injectables by Geographic Region
4.1 World Historic Aesthetic Injectables Market Size by Geographic Region (2021-2026)
4.1.1 Global Aesthetic Injectables Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Aesthetic Injectables Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Aesthetic Injectables Market Size by Country/Region (2021-2026)
4.2.1 Global Aesthetic Injectables Annual Sales by Country/Region (2021-2026)
4.2.2 Global Aesthetic Injectables Annual Revenue by Country/Region (2021-2026)
4.3 Americas Aesthetic Injectables Sales Growth
4.4 APAC Aesthetic Injectables Sales Growth
4.5 Europe Aesthetic Injectables Sales Growth
4.6 Middle East & Africa Aesthetic Injectables Sales Growth

5 Americas
5.1 Americas Aesthetic Injectables Sales by Country
5.1.1 Americas Aesthetic Injectables Sales by Country (2021-2026)
5.1.2 Americas Aesthetic Injectables Revenue by Country (2021-2026)
5.2 Americas Aesthetic Injectables Sales by Type (2021-2026)
5.3 Americas Aesthetic Injectables Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil

6 APAC
6.1 APAC Aesthetic Injectables Sales by Region
6.1.1 APAC Aesthetic Injectables Sales by Region (2021-2026)
6.1.2 APAC Aesthetic Injectables Revenue by Region (2021-2026)
6.2 APAC Aesthetic Injectables Sales by Type (2021-2026)
6.3 APAC Aesthetic Injectables Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan

7 Europe
7.1 Europe Aesthetic Injectables by Country
7.1.1 Europe Aesthetic Injectables Sales by Country (2021-2026)
7.1.2 Europe Aesthetic Injectables Revenue by Country (2021-2026)
7.2 Europe Aesthetic Injectables Sales by Type (2021-2026)
7.3 Europe Aesthetic Injectables Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia

8 Middle East & Africa
8.1 Middle East & Africa Aesthetic Injectables by Country
8.1.1 Middle East & Africa Aesthetic Injectables Sales by Country (2021-2026)
8.1.2 Middle East & Africa Aesthetic Injectables Revenue by Country (2021-2026)
8.2 Middle East & Africa Aesthetic Injectables Sales by Type (2021-2026)
8.3 Middle East & Africa Aesthetic Injectables Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries

9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends

10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Aesthetic Injectables
10.3 Manufacturing Process Analysis of Aesthetic Injectables
10.4 Industry Chain Structure of Aesthetic Injectables

11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Aesthetic Injectables Distributors
11.3 Aesthetic Injectables Customer

12 World Forecast Review for Aesthetic Injectables by Geographic Region
12.1 Global Aesthetic Injectables Market Size Forecast by Region
12.1.1 Global Aesthetic Injectables Forecast by Region (2027-2032)
12.1.2 Global Aesthetic Injectables Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Aesthetic Injectables Forecast by Type (2027-2032)
12.7 Global Aesthetic Injectables Forecast by Application (2027-2032)

13 Key Players Analysis
13.1 AbbVie Inc.
13.1.1 AbbVie Inc. Company Information
13.1.2 AbbVie Inc. Aesthetic Injectables Product Portfolios and Specifications
13.1.3 AbbVie Inc. Aesthetic Injectables Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 AbbVie Inc. Main Business Overview
13.1.5 AbbVie Inc. Latest Developments
13.2 Galderma Group AG
13.2.1 Galderma Group AG Company Information
13.2.2 Galderma Group AG Aesthetic Injectables Product Portfolios and Specifications
13.2.3 Galderma Group AG Aesthetic Injectables Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Galderma Group AG Main Business Overview
13.2.5 Galderma Group AG Latest Developments
13.3 Merz Pharma GmbH & Co. KGaA
13.3.1 Merz Pharma GmbH & Co. KGaA Company Information
13.3.2 Merz Pharma GmbH & Co. KGaA Aesthetic Injectables Product Portfolios and Specifications
13.3.3 Merz Pharma GmbH & Co. KGaA Aesthetic Injectables Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Merz Pharma GmbH & Co. KGaA Main Business Overview
13.3.5 Merz Pharma GmbH & Co. KGaA Latest Developments
13.4 Ipsen S.A.
13.4.1 Ipsen S.A. Company Information
13.4.2 Ipsen S.A. Aesthetic Injectables Product Portfolios and Specifications
13.4.3 Ipsen S.A. Aesthetic Injectables Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Ipsen S.A. Main Business Overview
13.4.5 Ipsen S.A. Latest Developments
13.5 Revance
13.5.1 Revance Company Information
13.5.2 Revance Aesthetic Injectables Product Portfolios and Specifications
13.5.3 Revance Aesthetic Injectables Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Revance Main Business Overview
13.5.5 Revance Latest Developments
13.6 Daewoong Pharmaceutical Co., Ltd.
13.6.1 Daewoong Pharmaceutical Co., Ltd. Company Information
13.6.2 Daewoong Pharmaceutical Co., Ltd. Aesthetic Injectables Product Portfolios and Specifications
13.6.3 Daewoong Pharmaceutical Co., Ltd. Aesthetic Injectables Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Daewoong Pharmaceutical Co., Ltd. Main Business Overview
13.6.5 Daewoong Pharmaceutical Co., Ltd. Latest Developments
13.7 Hugel, Inc.
13.7.1 Hugel, Inc. Company Information
13.7.2 Hugel, Inc. Aesthetic Injectables Product Portfolios and Specifications
13.7.3 Hugel, Inc. Aesthetic Injectables Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Hugel, Inc. Main Business Overview
13.7.5 Hugel, Inc. Latest Developments
13.8 Medytox Inc.
13.8.1 Medytox Inc. Company Information
13.8.2 Medytox Inc. Aesthetic Injectables Product Portfolios and Specifications
13.8.3 Medytox Inc. Aesthetic Injectables Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Medytox Inc. Main Business Overview
13.8.5 Medytox Inc. Latest Developments
13.9 Huons BioPharma Co., Ltd.
13.9.1 Huons BioPharma Co., Ltd. Company Information
13.9.2 Huons BioPharma Co., Ltd. Aesthetic Injectables Product Portfolios and Specifications
13.9.3 Huons BioPharma Co., Ltd. Aesthetic Injectables Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Huons BioPharma Co., Ltd. Main Business Overview
13.9.5 Huons BioPharma Co., Ltd. Latest Developments
13.10 LG Chem, Ltd.
13.10.1 LG Chem, Ltd. Company Information
13.10.2 LG Chem, Ltd. Aesthetic Injectables Product Portfolios and Specifications
13.10.3 LG Chem, Ltd. Aesthetic Injectables Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 LG Chem, Ltd. Main Business Overview
13.10.5 LG Chem, Ltd. Latest Developments
13.11 Teoxane SA
13.11.1 Teoxane SA Company Information
13.11.2 Teoxane SA Aesthetic Injectables Product Portfolios and Specifications
13.11.3 Teoxane SA Aesthetic Injectables Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 Teoxane SA Main Business Overview
13.11.5 Teoxane SA Latest Developments
13.12 Croma-Pharma GmbH
13.12.1 Croma-Pharma GmbH Company Information
13.12.2 Croma-Pharma GmbH Aesthetic Injectables Product Portfolios and Specifications
13.12.3 Croma-Pharma GmbH Aesthetic Injectables Sales, Revenue, Price and Gross Margin (2021-2026)
13.12.4 Croma-Pharma GmbH Main Business Overview
13.12.5 Croma-Pharma GmbH Latest Developments
13.13 IBSA Institut Biochimique SA
13.13.1 IBSA Institut Biochimique SA Company Information
13.13.2 IBSA Institut Biochimique SA Aesthetic Injectables Product Portfolios and Specifications
13.13.3 IBSA Institut Biochimique SA Aesthetic Injectables Sales, Revenue, Price and Gross Margin (2021-2026)
13.13.4 IBSA Institut Biochimique SA Main Business Overview
13.13.5 IBSA Institut Biochimique SA Latest Developments
13.14 Prollenium Medical Technologies Inc.
13.14.1 Prollenium Medical Technologies Inc. Company Information
13.14.2 Prollenium Medical Technologies Inc. Aesthetic Injectables Product Portfolios and Specifications
13.14.3 Prollenium Medical Technologies Inc. Aesthetic Injectables Sales, Revenue, Price and Gross Margin (2021-2026)
13.14.4 Prollenium Medical Technologies Inc. Main Business Overview
13.14.5 Prollenium Medical Technologies Inc. Latest Developments
13.15 Laboratoires VIVACY
13.15.1 Laboratoires VIVACY Company Information
13.15.2 Laboratoires VIVACY Aesthetic Injectables Product Portfolios and Specifications
13.15.3 Laboratoires VIVACY Aesthetic Injectables Sales, Revenue, Price and Gross Margin (2021-2026)
13.15.4 Laboratoires VIVACY Main Business Overview
13.15.5 Laboratoires VIVACY Latest Developments
13.16 BioScience GmbH
13.16.1 BioScience GmbH Company Information
13.16.2 BioScience GmbH Aesthetic Injectables Product Portfolios and Specifications
13.16.3 BioScience GmbH Aesthetic Injectables Sales, Revenue, Price and Gross Margin (2021-2026)
13.16.4 BioScience GmbH Main Business Overview
13.16.5 BioScience GmbH Latest Developments
13.17 MATEX LAB S.p.A.
13.17.1 MATEX LAB S.p.A. Company Information
13.17.2 MATEX LAB S.p.A. Aesthetic Injectables Product Portfolios and Specifications
13.17.3 MATEX LAB S.p.A. Aesthetic Injectables Sales, Revenue, Price and Gross Margin (2021-2026)
13.17.4 MATEX LAB S.p.A. Main Business Overview
13.17.5 MATEX LAB S.p.A. Latest Developments
13.18 SYMATESE
13.18.1 SYMATESE Company Information
13.18.2 SYMATESE Aesthetic Injectables Product Portfolios and Specifications
13.18.3 SYMATESE Aesthetic Injectables Sales, Revenue, Price and Gross Margin (2021-2026)
13.18.4 SYMATESE Main Business Overview
13.18.5 SYMATESE Latest Developments
13.19 Tiger Aesthetics Medical, LLC
13.19.1 Tiger Aesthetics Medical, LLC Company Information
13.19.2 Tiger Aesthetics Medical, LLC Aesthetic Injectables Product Portfolios and Specifications
13.19.3 Tiger Aesthetics Medical, LLC Aesthetic Injectables Sales, Revenue, Price and Gross Margin (2021-2026)
13.19.4 Tiger Aesthetics Medical, LLC Main Business Overview
13.19.5 Tiger Aesthetics Medical, LLC Latest Developments
13.20 Mastelli S.r.l.
13.20.1 Mastelli S.r.l. Company Information
13.20.2 Mastelli S.r.l. Aesthetic Injectables Product Portfolios and Specifications
13.20.3 Mastelli S.r.l. Aesthetic Injectables Sales, Revenue, Price and Gross Margin (2021-2026)
13.20.4 Mastelli S.r.l. Main Business Overview
13.20.5 Mastelli S.r.l. Latest Developments
13.21 PharmaResearch Co., Ltd.
13.21.1 PharmaResearch Co., Ltd. Company Information
13.21.2 PharmaResearch Co., Ltd. Aesthetic Injectables Product Portfolios and Specifications
13.21.3 PharmaResearch Co., Ltd. Aesthetic Injectables Sales, Revenue, Price and Gross Margin (2021-2026)
13.21.4 PharmaResearch Co., Ltd. Main Business Overview
13.21.5 PharmaResearch Co., Ltd. Latest Developments
13.22 REGEN Biotech, Inc.
13.22.1 REGEN Biotech, Inc. Company Information
13.22.2 REGEN Biotech, Inc. Aesthetic Injectables Product Portfolios and Specifications
13.22.3 REGEN Biotech, Inc. Aesthetic Injectables Sales, Revenue, Price and Gross Margin (2021-2026)
13.22.4 REGEN Biotech, Inc. Main Business Overview
13.22.5 REGEN Biotech, Inc. Latest Developments
13.23 CGBIO Co., Ltd.
13.23.1 CGBIO Co., Ltd. Company Information
13.23.2 CGBIO Co., Ltd. Aesthetic Injectables Product Portfolios and Specifications
13.23.3 CGBIO Co., Ltd. Aesthetic Injectables Sales, Revenue, Price and Gross Margin (2021-2026)
13.23.4 CGBIO Co., Ltd. Main Business Overview
13.23.5 CGBIO Co., Ltd. Latest Developments
13.24 DEXLEVO Inc.
13.24.1 DEXLEVO Inc. Company Information
13.24.2 DEXLEVO Inc. Aesthetic Injectables Product Portfolios and Specifications
13.24.3 DEXLEVO Inc. Aesthetic Injectables Sales, Revenue, Price and Gross Margin (2021-2026)
13.24.4 DEXLEVO Inc. Main Business Overview
13.24.5 DEXLEVO Inc. Latest Developments
13.25 BioPlus Co., Ltd.
13.25.1 BioPlus Co., Ltd. Company Information
13.25.2 BioPlus Co., Ltd. Aesthetic Injectables Product Portfolios and Specifications
13.25.3 BioPlus Co., Ltd. Aesthetic Injectables Sales, Revenue, Price and Gross Margin (2021-2026)
13.25.4 BioPlus Co., Ltd. Main Business Overview
13.25.5 BioPlus Co., Ltd. Latest Developments
13.26 Humedix Co., Ltd.
13.26.1 Humedix Co., Ltd. Company Information
13.26.2 Humedix Co., Ltd. Aesthetic Injectables Product Portfolios and Specifications
13.26.3 Humedix Co., Ltd. Aesthetic Injectables Sales, Revenue, Price and Gross Margin (2021-2026)
13.26.4 Humedix Co., Ltd. Main Business Overview
13.26.5 Humedix Co., Ltd. Latest Developments
13.27 Across Co., Ltd.
13.27.1 Across Co., Ltd. Company Information
13.27.2 Across Co., Ltd. Aesthetic Injectables Product Portfolios and Specifications
13.27.3 Across Co., Ltd. Aesthetic Injectables Sales, Revenue, Price and Gross Margin (2021-2026)
13.27.4 Across Co., Ltd. Main Business Overview
13.27.5 Across Co., Ltd. Latest Developments
13.28 JETEMA Co., Ltd.
13.28.1 JETEMA Co., Ltd. Company Information
13.28.2 JETEMA Co., Ltd. Aesthetic Injectables Product Portfolios and Specifications
13.28.3 JETEMA Co., Ltd. Aesthetic Injectables Sales, Revenue, Price and Gross Margin (2021-2026)
13.28.4 JETEMA Co., Ltd. Main Business Overview
13.28.5 JETEMA Co., Ltd. Latest Developments
13.29 GENOSS Co., Ltd.
13.29.1 GENOSS Co., Ltd. Company Information
13.29.2 GENOSS Co., Ltd. Aesthetic Injectables Product Portfolios and Specifications
13.29.3 GENOSS Co., Ltd. Aesthetic Injectables Sales, Revenue, Price and Gross Margin (2021-2026)
13.29.4 GENOSS Co., Ltd. Main Business Overview
13.29.5 GENOSS Co., Ltd. Latest Developments
13.30 BNC Korea Co., Ltd.
13.30.1 BNC Korea Co., Ltd. Company Information
13.30.2 BNC Korea Co., Ltd. Aesthetic Injectables Product Portfolios and Specifications
13.30.3 BNC Korea Co., Ltd. Aesthetic Injectables Sales, Revenue, Price and Gross Margin (2021-2026)
13.30.4 BNC Korea Co., Ltd. Main Business Overview
13.30.5 BNC Korea Co., Ltd. Latest Developments
13.31 SciVision Biotech Inc.
13.31.1 SciVision Biotech Inc. Company Information
13.31.2 SciVision Biotech Inc. Aesthetic Injectables Product Portfolios and Specifications
13.31.3 SciVision Biotech Inc. Aesthetic Injectables Sales, Revenue, Price and Gross Margin (2021-2026)
13.31.4 SciVision Biotech Inc. Main Business Overview
13.31.5 SciVision Biotech Inc. Latest Developments
13.32 Sunmax Biotechnology Co., Ltd.
13.32.1 Sunmax Biotechnology Co., Ltd. Company Information
13.32.2 Sunmax Biotechnology Co., Ltd. Aesthetic Injectables Product Portfolios and Specifications
13.32.3 Sunmax Biotechnology Co., Ltd. Aesthetic Injectables Sales, Revenue, Price and Gross Margin (2021-2026)
13.32.4 Sunmax Biotechnology Co., Ltd. Main Business Overview
13.32.5 Sunmax Biotechnology Co., Ltd. Latest Developments
13.33 NPO Microgen
13.33.1 NPO Microgen Company Information
13.33.2 NPO Microgen Aesthetic Injectables Product Portfolios and Specifications
13.33.3 NPO Microgen Aesthetic Injectables Sales, Revenue, Price and Gross Margin (2021-2026)
13.33.4 NPO Microgen Main Business Overview
13.33.5 NPO Microgen Latest Developments
13.34 Huadong Medicine Co., Ltd.
13.34.1 Huadong Medicine Co., Ltd. Company Information
13.34.2 Huadong Medicine Co., Ltd. Aesthetic Injectables Product Portfolios and Specifications
13.34.3 Huadong Medicine Co., Ltd. Aesthetic Injectables Sales, Revenue, Price and Gross Margin (2021-2026)
13.34.4 Huadong Medicine Co., Ltd. Main Business Overview
13.34.5 Huadong Medicine Co., Ltd. Latest Developments
13.35 Bloomage Biotechnology Corporation Limited
13.35.1 Bloomage Biotechnology Corporation Limited Company Information
13.35.2 Bloomage Biotechnology Corporation Limited Aesthetic Injectables Product Portfolios and Specifications
13.35.3 Bloomage Biotechnology Corporation Limited Aesthetic Injectables Sales, Revenue, Price and Gross Margin (2021-2026)
13.35.4 Bloomage Biotechnology Corporation Limited Main Business Overview
13.35.5 Bloomage Biotechnology Corporation Limited Latest Developments
13.36 IMEIK Technology Development Co., Ltd.
13.36.1 IMEIK Technology Development Co., Ltd. Company Information
13.36.2 IMEIK Technology Development Co., Ltd. Aesthetic Injectables Product Portfolios and Specifications
13.36.3 IMEIK Technology Development Co., Ltd. Aesthetic Injectables Sales, Revenue, Price and Gross Margin (2021-2026)
13.36.4 IMEIK Technology Development Co., Ltd. Main Business Overview
13.36.5 IMEIK Technology Development Co., Ltd. Latest Developments
13.37 Shanghai Haohai Biological Technology Co., Ltd.
13.37.1 Shanghai Haohai Biological Technology Co., Ltd. Company Information
13.37.2 Shanghai Haohai Biological Technology Co., Ltd. Aesthetic Injectables Product Portfolios and Specifications
13.37.3 Shanghai Haohai Biological Technology Co., Ltd. Aesthetic Injectables Sales, Revenue, Price and Gross Margin (2021-2026)
13.37.4 Shanghai Haohai Biological Technology Co., Ltd. Main Business Overview
13.37.5 Shanghai Haohai Biological Technology Co., Ltd. Latest Developments
13.38 Shanxi Jinbo Bio-Pharmaceutical Co., Ltd.
13.38.1 Shanxi Jinbo Bio-Pharmaceutical Co., Ltd. Company Information
13.38.2 Shanxi Jinbo Bio-Pharmaceutical Co., Ltd. Aesthetic Injectables Product Portfolios and Specifications
13.38.3 Shanxi Jinbo Bio-Pharmaceutical Co., Ltd. Aesthetic Injectables Sales, Revenue, Price and Gross Margin (2021-2026)
13.38.4 Shanxi Jinbo Bio-Pharmaceutical Co., Ltd. Main Business Overview
13.38.5 Shanxi Jinbo Bio-Pharmaceutical Co., Ltd. Latest Developments
13.39 Lanzhou Institute of Biological Products Co., Ltd.
13.39.1 Lanzhou Institute of Biological Products Co., Ltd. Company Information
13.39.2 Lanzhou Institute of Biological Products Co., Ltd. Aesthetic Injectables Product Portfolios and Specifications
13.39.3 Lanzhou Institute of Biological Products Co., Ltd. Aesthetic Injectables Sales, Revenue, Price and Gross Margin (2021-2026)
13.39.4 Lanzhou Institute of Biological Products Co., Ltd. Main Business Overview
13.39.5 Lanzhou Institute of Biological Products Co., Ltd. Latest Developments
13.40 Bohus BioTech
13.40.1 Bohus BioTech Company Information
13.40.2 Bohus BioTech Aesthetic Injectables Product Portfolios and Specifications
13.40.3 Bohus BioTech Aesthetic Injectables Sales, Revenue, Price and Gross Margin (2021-2026)
13.40.4 Bohus BioTech Main Business Overview
13.40.5 Bohus BioTech Latest Developments

14 Research Findings and Conclusion

ページTOPに戻る

List of Tables/Graphs

List of Tables
Table 1. Aesthetic Injectables Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Aesthetic Injectables Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Aesthetic Botulinum Toxin
Table 4. Major Players of HA-based Injectables
Table 5. Major Players of PLLA & PDLLA Injectables
Table 6. Major Players of CaHA Injectables
Table 7. Major Players of Others
Table 8. Global Aesthetic Injectables Sales by Type (2021-2026) & (K Units)
Table 9. Global Aesthetic Injectables Sales Market Share by Type (2021-2026)
Table 10. Global Aesthetic Injectables Revenue by Type (2021-2026) & ($ million)
Table 11. Global Aesthetic Injectables Revenue Market Share by Type (2021-2026)
Table 12. Global Aesthetic Injectables Sale Price by Type (2021-2026) & (US$/Unit)
Table 13. Major Players of Lyophilized Powder Vial
Table 14. Major Players of Ready-to-use Liquid Toxin
Table 15. Major Players of Reconstituted Microsphere/Polymer Vial
Table 16. Major Players of Others
Table 17. Global Aesthetic Injectables Sales by Product Presentation (2021-2026) & (K Units)
Table 18. Global Aesthetic Injectables Sales Market Share by Product Presentation (2021-2026)
Table 19. Global Aesthetic Injectables Revenue by Product Presentation (2021-2026) & ($ million)
Table 20. Global Aesthetic Injectables Revenue Market Share by Product Presentation (2021-2026)
Table 21. Global Aesthetic Injectables Sale Price by Product Presentation (2021-2026) & (US$/Unit)
Table 22. Major Players of Up to 6 Months
Table 23. Major Players of More than 6 Months to 12 Months
Table 24. Major Players of More than 12 Months to 24 Months
Table 25. Major Players of More than 24 Months / Semi-permanent
Table 26. Global Aesthetic Injectables Sales by Effect Duration (2021-2026) & (K Units)
Table 27. Global Aesthetic Injectables Sales Market Share by Effect Duration (2021-2026)
Table 28. Global Aesthetic Injectables Revenue by Effect Duration (2021-2026) & ($ million)
Table 29. Global Aesthetic Injectables Revenue Market Share by Effect Duration (2021-2026)
Table 30. Global Aesthetic Injectables Sale Price by Effect Duration (2021-2026) & (US$/Unit)
Table 31. Global Aesthetic Injectables Sale by Application (2021-2026) & (K Units)
Table 32. Global Aesthetic Injectables Sale Market Share by Application (2021-2026)
Table 33. Global Aesthetic Injectables Revenue by Application (2021-2026) & ($ million)
Table 34. Global Aesthetic Injectables Revenue Market Share by Application (2021-2026)
Table 35. Global Aesthetic Injectables Sale Price by Application (2021-2026) & (US$/Unit)
Table 36. Global Aesthetic Injectables Sales by Company (2021-2026) & (K Units)
Table 37. Global Aesthetic Injectables Sales Market Share by Company (2021-2026)
Table 38. Global Aesthetic Injectables Revenue by Company (2021-2026) & ($ millions)
Table 39. Global Aesthetic Injectables Revenue Market Share by Company (2021-2026)
Table 40. Global Aesthetic Injectables Sale Price by Company (2021-2026) & (US$/Unit)
Table 41. Key Manufacturers Aesthetic Injectables Producing Area Distribution and Sales Area
Table 42. Players Aesthetic Injectables Products Offered
Table 43. Aesthetic Injectables Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 44. New Products and Potential Entrants
Table 45. Market M&A Activity & Strategy
Table 46. Global Aesthetic Injectables Sales by Geographic Region (2021-2026) & (K Units)
Table 47. Global Aesthetic Injectables Sales Market Share Geographic Region (2021-2026)
Table 48. Global Aesthetic Injectables Revenue by Geographic Region (2021-2026) & ($ millions)
Table 49. Global Aesthetic Injectables Revenue Market Share by Geographic Region (2021-2026)
Table 50. Global Aesthetic Injectables Sales by Country/Region (2021-2026) & (K Units)
Table 51. Global Aesthetic Injectables Sales Market Share by Country/Region (2021-2026)
Table 52. Global Aesthetic Injectables Revenue by Country/Region (2021-2026) & ($ millions)
Table 53. Global Aesthetic Injectables Revenue Market Share by Country/Region (2021-2026)
Table 54. Americas Aesthetic Injectables Sales by Country (2021-2026) & (K Units)
Table 55. Americas Aesthetic Injectables Sales Market Share by Country (2021-2026)
Table 56. Americas Aesthetic Injectables Revenue by Country (2021-2026) & ($ millions)
Table 57. Americas Aesthetic Injectables Sales by Type (2021-2026) & (K Units)
Table 58. Americas Aesthetic Injectables Sales by Application (2021-2026) & (K Units)
Table 59. APAC Aesthetic Injectables Sales by Region (2021-2026) & (K Units)
Table 60. APAC Aesthetic Injectables Sales Market Share by Region (2021-2026)
Table 61. APAC Aesthetic Injectables Revenue by Region (2021-2026) & ($ millions)
Table 62. APAC Aesthetic Injectables Sales by Type (2021-2026) & (K Units)
Table 63. APAC Aesthetic Injectables Sales by Application (2021-2026) & (K Units)
Table 64. Europe Aesthetic Injectables Sales by Country (2021-2026) & (K Units)
Table 65. Europe Aesthetic Injectables Revenue by Country (2021-2026) & ($ millions)
Table 66. Europe Aesthetic Injectables Sales by Type (2021-2026) & (K Units)
Table 67. Europe Aesthetic Injectables Sales by Application (2021-2026) & (K Units)
Table 68. Middle East & Africa Aesthetic Injectables Sales by Country (2021-2026) & (K Units)
Table 69. Middle East & Africa Aesthetic Injectables Revenue Market Share by Country (2021-2026)
Table 70. Middle East & Africa Aesthetic Injectables Sales by Type (2021-2026) & (K Units)
Table 71. Middle East & Africa Aesthetic Injectables Sales by Application (2021-2026) & (K Units)
Table 72. Key Market Drivers & Growth Opportunities of Aesthetic Injectables
Table 73. Key Market Challenges & Risks of Aesthetic Injectables
Table 74. Key Industry Trends of Aesthetic Injectables
Table 75. Aesthetic Injectables Raw Material
Table 76. Key Suppliers of Raw Materials
Table 77. Aesthetic Injectables Distributors List
Table 78. Aesthetic Injectables Customer List
Table 79. Global Aesthetic Injectables Sales Forecast by Region (2027-2032) & (K Units)
Table 80. Global Aesthetic Injectables Revenue Forecast by Region (2027-2032) & ($ millions)
Table 81. Americas Aesthetic Injectables Sales Forecast by Country (2027-2032) & (K Units)
Table 82. Americas Aesthetic Injectables Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 83. APAC Aesthetic Injectables Sales Forecast by Region (2027-2032) & (K Units)
Table 84. APAC Aesthetic Injectables Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 85. Europe Aesthetic Injectables Sales Forecast by Country (2027-2032) & (K Units)
Table 86. Europe Aesthetic Injectables Revenue Forecast by Country (2027-2032) & ($ millions)
Table 87. Middle East & Africa Aesthetic Injectables Sales Forecast by Country (2027-2032) & (K Units)
Table 88. Middle East & Africa Aesthetic Injectables Revenue Forecast by Country (2027-2032) & ($ millions)
Table 89. Global Aesthetic Injectables Sales Forecast by Type (2027-2032) & (K Units)
Table 90. Global Aesthetic Injectables Revenue Forecast by Type (2027-2032) & ($ millions)
Table 91. Global Aesthetic Injectables Sales Forecast by Application (2027-2032) & (K Units)
Table 92. Global Aesthetic Injectables Revenue Forecast by Application (2027-2032) & ($ millions)
Table 93. AbbVie Inc. Basic Information, Aesthetic Injectables Manufacturing Base, Sales Area and Its Competitors
Table 94. AbbVie Inc. Aesthetic Injectables Product Portfolios and Specifications
Table 95. AbbVie Inc. Aesthetic Injectables Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 96. AbbVie Inc. Main Business
Table 97. AbbVie Inc. Latest Developments
Table 98. Galderma Group AG Basic Information, Aesthetic Injectables Manufacturing Base, Sales Area and Its Competitors
Table 99. Galderma Group AG Aesthetic Injectables Product Portfolios and Specifications
Table 100. Galderma Group AG Aesthetic Injectables Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 101. Galderma Group AG Main Business
Table 102. Galderma Group AG Latest Developments
Table 103. Merz Pharma GmbH & Co. KGaA Basic Information, Aesthetic Injectables Manufacturing Base, Sales Area and Its Competitors
Table 104. Merz Pharma GmbH & Co. KGaA Aesthetic Injectables Product Portfolios and Specifications
Table 105. Merz Pharma GmbH & Co. KGaA Aesthetic Injectables Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 106. Merz Pharma GmbH & Co. KGaA Main Business
Table 107. Merz Pharma GmbH & Co. KGaA Latest Developments
Table 108. Ipsen S.A. Basic Information, Aesthetic Injectables Manufacturing Base, Sales Area and Its Competitors
Table 109. Ipsen S.A. Aesthetic Injectables Product Portfolios and Specifications
Table 110. Ipsen S.A. Aesthetic Injectables Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 111. Ipsen S.A. Main Business
Table 112. Ipsen S.A. Latest Developments
Table 113. Revance Basic Information, Aesthetic Injectables Manufacturing Base, Sales Area and Its Competitors
Table 114. Revance Aesthetic Injectables Product Portfolios and Specifications
Table 115. Revance Aesthetic Injectables Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 116. Revance Main Business
Table 117. Revance Latest Developments
Table 118. Daewoong Pharmaceutical Co., Ltd. Basic Information, Aesthetic Injectables Manufacturing Base, Sales Area and Its Competitors
Table 119. Daewoong Pharmaceutical Co., Ltd. Aesthetic Injectables Product Portfolios and Specifications
Table 120. Daewoong Pharmaceutical Co., Ltd. Aesthetic Injectables Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 121. Daewoong Pharmaceutical Co., Ltd. Main Business
Table 122. Daewoong Pharmaceutical Co., Ltd. Latest Developments
Table 123. Hugel, Inc. Basic Information, Aesthetic Injectables Manufacturing Base, Sales Area and Its Competitors
Table 124. Hugel, Inc. Aesthetic Injectables Product Portfolios and Specifications
Table 125. Hugel, Inc. Aesthetic Injectables Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 126. Hugel, Inc. Main Business
Table 127. Hugel, Inc. Latest Developments
Table 128. Medytox Inc. Basic Information, Aesthetic Injectables Manufacturing Base, Sales Area and Its Competitors
Table 129. Medytox Inc. Aesthetic Injectables Product Portfolios and Specifications
Table 130. Medytox Inc. Aesthetic Injectables Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 131. Medytox Inc. Main Business
Table 132. Medytox Inc. Latest Developments
Table 133. Huons BioPharma Co., Ltd. Basic Information, Aesthetic Injectables Manufacturing Base, Sales Area and Its Competitors
Table 134. Huons BioPharma Co., Ltd. Aesthetic Injectables Product Portfolios and Specifications
Table 135. Huons BioPharma Co., Ltd. Aesthetic Injectables Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 136. Huons BioPharma Co., Ltd. Main Business
Table 137. Huons BioPharma Co., Ltd. Latest Developments
Table 138. LG Chem, Ltd. Basic Information, Aesthetic Injectables Manufacturing Base, Sales Area and Its Competitors
Table 139. LG Chem, Ltd. Aesthetic Injectables Product Portfolios and Specifications
Table 140. LG Chem, Ltd. Aesthetic Injectables Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 141. LG Chem, Ltd. Main Business
Table 142. LG Chem, Ltd. Latest Developments
Table 143. Teoxane SA Basic Information, Aesthetic Injectables Manufacturing Base, Sales Area and Its Competitors
Table 144. Teoxane SA Aesthetic Injectables Product Portfolios and Specifications
Table 145. Teoxane SA Aesthetic Injectables Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 146. Teoxane SA Main Business
Table 147. Teoxane SA Latest Developments
Table 148. Croma-Pharma GmbH Basic Information, Aesthetic Injectables Manufacturing Base, Sales Area and Its Competitors
Table 149. Croma-Pharma GmbH Aesthetic Injectables Product Portfolios and Specifications
Table 150. Croma-Pharma GmbH Aesthetic Injectables Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 151. Croma-Pharma GmbH Main Business
Table 152. Croma-Pharma GmbH Latest Developments
Table 153. IBSA Institut Biochimique SA Basic Information, Aesthetic Injectables Manufacturing Base, Sales Area and Its Competitors
Table 154. IBSA Institut Biochimique SA Aesthetic Injectables Product Portfolios and Specifications
Table 155. IBSA Institut Biochimique SA Aesthetic Injectables Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 156. IBSA Institut Biochimique SA Main Business
Table 157. IBSA Institut Biochimique SA Latest Developments
Table 158. Prollenium Medical Technologies Inc. Basic Information, Aesthetic Injectables Manufacturing Base, Sales Area and Its Competitors
Table 159. Prollenium Medical Technologies Inc. Aesthetic Injectables Product Portfolios and Specifications
Table 160. Prollenium Medical Technologies Inc. Aesthetic Injectables Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 161. Prollenium Medical Technologies Inc. Main Business
Table 162. Prollenium Medical Technologies Inc. Latest Developments
Table 163. Laboratoires VIVACY Basic Information, Aesthetic Injectables Manufacturing Base, Sales Area and Its Competitors
Table 164. Laboratoires VIVACY Aesthetic Injectables Product Portfolios and Specifications
Table 165. Laboratoires VIVACY Aesthetic Injectables Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 166. Laboratoires VIVACY Main Business
Table 167. Laboratoires VIVACY Latest Developments
Table 168. BioScience GmbH Basic Information, Aesthetic Injectables Manufacturing Base, Sales Area and Its Competitors
Table 169. BioScience GmbH Aesthetic Injectables Product Portfolios and Specifications
Table 170. BioScience GmbH Aesthetic Injectables Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 171. BioScience GmbH Main Business
Table 172. BioScience GmbH Latest Developments
Table 173. MATEX LAB S.p.A. Basic Information, Aesthetic Injectables Manufacturing Base, Sales Area and Its Competitors
Table 174. MATEX LAB S.p.A. Aesthetic Injectables Product Portfolios and Specifications
Table 175. MATEX LAB S.p.A. Aesthetic Injectables Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 176. MATEX LAB S.p.A. Main Business
Table 177. MATEX LAB S.p.A. Latest Developments
Table 178. SYMATESE Basic Information, Aesthetic Injectables Manufacturing Base, Sales Area and Its Competitors
Table 179. SYMATESE Aesthetic Injectables Product Portfolios and Specifications
Table 180. SYMATESE Aesthetic Injectables Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 181. SYMATESE Main Business
Table 182. SYMATESE Latest Developments
Table 183. Tiger Aesthetics Medical, LLC Basic Information, Aesthetic Injectables Manufacturing Base, Sales Area and Its Competitors
Table 184. Tiger Aesthetics Medical, LLC Aesthetic Injectables Product Portfolios and Specifications
Table 185. Tiger Aesthetics Medical, LLC Aesthetic Injectables Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 186. Tiger Aesthetics Medical, LLC Main Business
Table 187. Tiger Aesthetics Medical, LLC Latest Developments
Table 188. Mastelli S.r.l. Basic Information, Aesthetic Injectables Manufacturing Base, Sales Area and Its Competitors
Table 189. Mastelli S.r.l. Aesthetic Injectables Product Portfolios and Specifications
Table 190. Mastelli S.r.l. Aesthetic Injectables Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 191. Mastelli S.r.l. Main Business
Table 192. Mastelli S.r.l. Latest Developments
Table 193. PharmaResearch Co., Ltd. Basic Information, Aesthetic Injectables Manufacturing Base, Sales Area and Its Competitors
Table 194. PharmaResearch Co., Ltd. Aesthetic Injectables Product Portfolios and Specifications
Table 195. PharmaResearch Co., Ltd. Aesthetic Injectables Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 196. PharmaResearch Co., Ltd. Main Business
Table 197. PharmaResearch Co., Ltd. Latest Developments
Table 198. REGEN Biotech, Inc. Basic Information, Aesthetic Injectables Manufacturing Base, Sales Area and Its Competitors
Table 199. REGEN Biotech, Inc. Aesthetic Injectables Product Portfolios and Specifications
Table 200. REGEN Biotech, Inc. Aesthetic Injectables Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 201. REGEN Biotech, Inc. Main Business
Table 202. REGEN Biotech, Inc. Latest Developments
Table 203. CGBIO Co., Ltd. Basic Information, Aesthetic Injectables Manufacturing Base, Sales Area and Its Competitors
Table 204. CGBIO Co., Ltd. Aesthetic Injectables Product Portfolios and Specifications
Table 205. CGBIO Co., Ltd. Aesthetic Injectables Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 206. CGBIO Co., Ltd. Main Business
Table 207. CGBIO Co., Ltd. Latest Developments
Table 208. DEXLEVO Inc. Basic Information, Aesthetic Injectables Manufacturing Base, Sales Area and Its Competitors
Table 209. DEXLEVO Inc. Aesthetic Injectables Product Portfolios and Specifications
Table 210. DEXLEVO Inc. Aesthetic Injectables Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 211. DEXLEVO Inc. Main Business
Table 212. DEXLEVO Inc. Latest Developments
Table 213. BioPlus Co., Ltd. Basic Information, Aesthetic Injectables Manufacturing Base, Sales Area and Its Competitors
Table 214. BioPlus Co., Ltd. Aesthetic Injectables Product Portfolios and Specifications
Table 215. BioPlus Co., Ltd. Aesthetic Injectables Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 216. BioPlus Co., Ltd. Main Business
Table 217. BioPlus Co., Ltd. Latest Developments
Table 218. Humedix Co., Ltd. Basic Information, Aesthetic Injectables Manufacturing Base, Sales Area and Its Competitors
Table 219. Humedix Co., Ltd. Aesthetic Injectables Product Portfolios and Specifications
Table 220. Humedix Co., Ltd. Aesthetic Injectables Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 221. Humedix Co., Ltd. Main Business
Table 222. Humedix Co., Ltd. Latest Developments
Table 223. Across Co., Ltd. Basic Information, Aesthetic Injectables Manufacturing Base, Sales Area and Its Competitors
Table 224. Across Co., Ltd. Aesthetic Injectables Product Portfolios and Specifications
Table 225. Across Co., Ltd. Aesthetic Injectables Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 226. Across Co., Ltd. Main Business
Table 227. Across Co., Ltd. Latest Developments
Table 228. JETEMA Co., Ltd. Basic Information, Aesthetic Injectables Manufacturing Base, Sales Area and Its Competitors
Table 229. JETEMA Co., Ltd. Aesthetic Injectables Product Portfolios and Specifications
Table 230. JETEMA Co., Ltd. Aesthetic Injectables Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 231. JETEMA Co., Ltd. Main Business
Table 232. JETEMA Co., Ltd. Latest Developments
Table 233. GENOSS Co., Ltd. Basic Information, Aesthetic Injectables Manufacturing Base, Sales Area and Its Competitors
Table 234. GENOSS Co., Ltd. Aesthetic Injectables Product Portfolios and Specifications
Table 235. GENOSS Co., Ltd. Aesthetic Injectables Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 236. GENOSS Co., Ltd. Main Business
Table 237. GENOSS Co., Ltd. Latest Developments
Table 238. BNC Korea Co., Ltd. Basic Information, Aesthetic Injectables Manufacturing Base, Sales Area and Its Competitors
Table 239. BNC Korea Co., Ltd. Aesthetic Injectables Product Portfolios and Specifications
Table 240. BNC Korea Co., Ltd. Aesthetic Injectables Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 241. BNC Korea Co., Ltd. Main Business
Table 242. BNC Korea Co., Ltd. Latest Developments
Table 243. SciVision Biotech Inc. Basic Information, Aesthetic Injectables Manufacturing Base, Sales Area and Its Competitors
Table 244. SciVision Biotech Inc. Aesthetic Injectables Product Portfolios and Specifications
Table 245. SciVision Biotech Inc. Aesthetic Injectables Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 246. SciVision Biotech Inc. Main Business
Table 247. SciVision Biotech Inc. Latest Developments
Table 248. Sunmax Biotechnology Co., Ltd. Basic Information, Aesthetic Injectables Manufacturing Base, Sales Area and Its Competitors
Table 249. Sunmax Biotechnology Co., Ltd. Aesthetic Injectables Product Portfolios and Specifications
Table 250. Sunmax Biotechnology Co., Ltd. Aesthetic Injectables Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 251. Sunmax Biotechnology Co., Ltd. Main Business
Table 252. Sunmax Biotechnology Co., Ltd. Latest Developments
Table 253. NPO Microgen Basic Information, Aesthetic Injectables Manufacturing Base, Sales Area and Its Competitors
Table 254. NPO Microgen Aesthetic Injectables Product Portfolios and Specifications
Table 255. NPO Microgen Aesthetic Injectables Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 256. NPO Microgen Main Business
Table 257. NPO Microgen Latest Developments
Table 258. Huadong Medicine Co., Ltd. Basic Information, Aesthetic Injectables Manufacturing Base, Sales Area and Its Competitors
Table 259. Huadong Medicine Co., Ltd. Aesthetic Injectables Product Portfolios and Specifications
Table 260. Huadong Medicine Co., Ltd. Aesthetic Injectables Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 261. Huadong Medicine Co., Ltd. Main Business
Table 262. Huadong Medicine Co., Ltd. Latest Developments
Table 263. Bloomage Biotechnology Corporation Limited Basic Information, Aesthetic Injectables Manufacturing Base, Sales Area and Its Competitors
Table 264. Bloomage Biotechnology Corporation Limited Aesthetic Injectables Product Portfolios and Specifications
Table 265. Bloomage Biotechnology Corporation Limited Aesthetic Injectables Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 266. Bloomage Biotechnology Corporation Limited Main Business
Table 267. Bloomage Biotechnology Corporation Limited Latest Developments
Table 268. IMEIK Technology Development Co., Ltd. Basic Information, Aesthetic Injectables Manufacturing Base, Sales Area and Its Competitors
Table 269. IMEIK Technology Development Co., Ltd. Aesthetic Injectables Product Portfolios and Specifications
Table 270. IMEIK Technology Development Co., Ltd. Aesthetic Injectables Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 271. IMEIK Technology Development Co., Ltd. Main Business
Table 272. IMEIK Technology Development Co., Ltd. Latest Developments
Table 273. Shanghai Haohai Biological Technology Co., Ltd. Basic Information, Aesthetic Injectables Manufacturing Base, Sales Area and Its Competitors
Table 274. Shanghai Haohai Biological Technology Co., Ltd. Aesthetic Injectables Product Portfolios and Specifications
Table 275. Shanghai Haohai Biological Technology Co., Ltd. Aesthetic Injectables Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 276. Shanghai Haohai Biological Technology Co., Ltd. Main Business
Table 277. Shanghai Haohai Biological Technology Co., Ltd. Latest Developments
Table 278. Shanxi Jinbo Bio-Pharmaceutical Co., Ltd. Basic Information, Aesthetic Injectables Manufacturing Base, Sales Area and Its Competitors
Table 279. Shanxi Jinbo Bio-Pharmaceutical Co., Ltd. Aesthetic Injectables Product Portfolios and Specifications
Table 280. Shanxi Jinbo Bio-Pharmaceutical Co., Ltd. Aesthetic Injectables Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 281. Shanxi Jinbo Bio-Pharmaceutical Co., Ltd. Main Business
Table 282. Shanxi Jinbo Bio-Pharmaceutical Co., Ltd. Latest Developments
Table 283. Lanzhou Institute of Biological Products Co., Ltd. Basic Information, Aesthetic Injectables Manufacturing Base, Sales Area and Its Competitors
Table 284. Lanzhou Institute of Biological Products Co., Ltd. Aesthetic Injectables Product Portfolios and Specifications
Table 285. Lanzhou Institute of Biological Products Co., Ltd. Aesthetic Injectables Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 286. Lanzhou Institute of Biological Products Co., Ltd. Main Business
Table 287. Lanzhou Institute of Biological Products Co., Ltd. Latest Developments
Table 288. Bohus BioTech Basic Information, Aesthetic Injectables Manufacturing Base, Sales Area and Its Competitors
Table 289. Bohus BioTech Aesthetic Injectables Product Portfolios and Specifications
Table 290. Bohus BioTech Aesthetic Injectables Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 291. Bohus BioTech Main Business
Table 292. Bohus BioTech Latest Developments

List of Figures
Figure 1. Picture of Aesthetic Injectables
Figure 2. Aesthetic Injectables Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Aesthetic Injectables Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Aesthetic Injectables Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Aesthetic Injectables Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Aesthetic Injectables Sales Market Share by Country/Region (2025)
Figure 10. Aesthetic Injectables Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Aesthetic Botulinum Toxin
Figure 12. Product Picture of HA-based Injectables
Figure 13. Product Picture of PLLA & PDLLA Injectables
Figure 14. Product Picture of CaHA Injectables
Figure 15. Product Picture of Others
Figure 16. Global Aesthetic Injectables Sales Market Share by Type in 2026
Figure 17. Global Aesthetic Injectables Revenue Market Share by Type (2021-2026)
Figure 18. Product Picture of Lyophilized Powder Vial
Figure 19. Product Picture of Ready-to-use Liquid Toxin
Figure 20. Product Picture of Reconstituted Microsphere/Polymer Vial
Figure 21. Product Picture of Others
Figure 22. Global Aesthetic Injectables Sales Market Share by Product Presentation in 2026
Figure 23. Global Aesthetic Injectables Revenue Market Share by Product Presentation (2021-2026)
Figure 24. Product Picture of Up to 6 Months
Figure 25. Product Picture of More than 6 Months to 12 Months
Figure 26. Product Picture of More than 12 Months to 24 Months
Figure 27. Product Picture of More than 24 Months / Semi-permanent
Figure 28. Global Aesthetic Injectables Sales Market Share by Effect Duration in 2026
Figure 29. Global Aesthetic Injectables Revenue Market Share by Effect Duration (2021-2026)
Figure 30. Aesthetic Injectables Consumed in Medical Aesthetic Clinics & Licensed Medspas
Figure 31. Global Aesthetic Injectables Market: Medical Aesthetic Clinics & Licensed Medspas (2021-2026) & (K Units)
Figure 32. Aesthetic Injectables Consumed in Dermatology Clinics
Figure 33. Global Aesthetic Injectables Market: Dermatology Clinics (2021-2026) & (K Units)
Figure 34. Aesthetic Injectables Consumed in Plastic & Cosmetic Surgery Clinics
Figure 35. Global Aesthetic Injectables Market: Plastic & Cosmetic Surgery Clinics (2021-2026) & (K Units)
Figure 36. Aesthetic Injectables Consumed in Hospitals & Medical Centers
Figure 37. Global Aesthetic Injectables Market: Hospitals & Medical Centers (2021-2026) & (K Units)
Figure 38. Aesthetic Injectables Consumed in Others
Figure 39. Global Aesthetic Injectables Market: Others (2021-2026) & (K Units)
Figure 40. Global Aesthetic Injectables Sale Market Share by Application (2025)
Figure 41. Global Aesthetic Injectables Revenue Market Share by Application in 2025
Figure 42. Aesthetic Injectables Sales by Company in 2025 (K Units)
Figure 43. Global Aesthetic Injectables Sales Market Share by Company in 2025
Figure 44. Aesthetic Injectables Revenue by Company in 2025 ($ millions)
Figure 45. Global Aesthetic Injectables Revenue Market Share by Company in 2025
Figure 46. Global Aesthetic Injectables Sales Market Share by Geographic Region (2021-2026)
Figure 47. Global Aesthetic Injectables Revenue Market Share by Geographic Region in 2025
Figure 48. Americas Aesthetic Injectables Sales 2021-2026 (K Units)
Figure 49. Americas Aesthetic Injectables Revenue 2021-2026 ($ millions)
Figure 50. APAC Aesthetic Injectables Sales 2021-2026 (K Units)
Figure 51. APAC Aesthetic Injectables Revenue 2021-2026 ($ millions)
Figure 52. Europe Aesthetic Injectables Sales 2021-2026 (K Units)
Figure 53. Europe Aesthetic Injectables Revenue 2021-2026 ($ millions)
Figure 54. Middle East & Africa Aesthetic Injectables Sales 2021-2026 (K Units)
Figure 55. Middle East & Africa Aesthetic Injectables Revenue 2021-2026 ($ millions)
Figure 56. Americas Aesthetic Injectables Sales Market Share by Country in 2025
Figure 57. Americas Aesthetic Injectables Revenue Market Share by Country (2021-2026)
Figure 58. Americas Aesthetic Injectables Sales Market Share by Type (2021-2026)